September 27, 2017

San Diego, CA – September 27, 2017 - Geom Therapeutics, Inc., today announced it has expanded its partnership with LegoChem Biosciences by entering into a license agreement for access to LegoChem Biosciences’ novel beta lactamase inhibitor (BLI) program. Geom’s pipeline, which addresses the rising incidence of multidrug-resistant (MDR) gram-negative pathogens, will be strengthened by the addition of the BLI program.

Geom’s lead candidate, GT-1, is a novel cephalosporin (beta-lactam) antibiotic with a unique mechanism of action and broad-spectrum activity against gram-negative pathogens, including MDR Pseudomonas aeruginosa and Acinetobacter species. GT-1 is being developed for the treatment of serious gram-negative infections in hospitalized patients. GT-1 will enter Phase 1 clinical studies in 2018 under a contract with the National Institute of Allergy and Infectious Diseases.

Geom plans to combine GT-1 with candidates from LegoChem Biosciences’ novel BLI program. BLIs inhibit bacteria...

Please reload

Recent Posts
Please reload

Please reload

Site map:

Contact Us